{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T21:33:55Z","timestamp":1768253635519,"version":"3.49.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1136\/ijgc-2022-003997","type":"journal-article","created":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T11:10:27Z","timestamp":1675681827000},"page":"514-520","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Genome tumor profiling in endometrial cancer and clinical relevance in endometrial cancer management: a retrospective single-center experience"],"prefix":"10.1016","volume":"33","clinical-trial-number":[{"clinical-trial-number":"nct03617679","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03745950","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03016338","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04634877","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05173987","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03884101","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03617679","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03745950","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03016338","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04634877","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05173987","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03884101","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05255653","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Vanda","family":"Salutari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viola","family":"Ghizzoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Vittoria","family":"Carbone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8763-6815","authenticated-orcid":false,"given":"Elena","family":"Giudice","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serena","family":"Cappuccio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1991-7284","authenticated-orcid":false,"given":"Francesco","family":"Fanfani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2758-1063","authenticated-orcid":false,"given":"Giovanni","family":"Scambia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0981-0598","authenticated-orcid":false,"given":"Domenica","family":"Lorusso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1136\/ijgc-2022-003997_bb0010","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1136\/ijgc-2022-003997_bb0015","first-page":"363","article-title":"Cancer treatment and survivorship statistics, 2019","volume":"69","author":"Miller","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"10.1136\/ijgc-2022-003997_bb0020","first-page":"7","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"10.1136\/ijgc-2022-003997_bb0025","unstructured":"National Comprehensive Cancer Network . NCCN guidelines - uterine neoplasms 2022. n.d.Available: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/uterine.pdf"},{"key":"10.1136\/ijgc-2022-003997_bb0030","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Kandoth","year":"2013","journal-title":"Nature"},{"key":"10.1136\/ijgc-2022-003997_bb0035","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1136\/ijgc-2020-002230","article-title":"ESGO\/ESTRO\/ESP guidelines for the management of patients with endometrial carcinoma","volume":"31","author":"Concin","year":"2021","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2022-003997_bb0040","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/bjc.2015.190","article-title":"A clinically applicable molecular-based classification for endometrial cancers","volume":"113","author":"Talhouk","year":"2015","journal-title":"Br J Cancer"},{"key":"10.1136\/ijgc-2022-003997_bb0045","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1200\/JCO.19.02627","article-title":"Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer","volume":"38","author":"Makker","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2022-003997_bb0050","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003777","volume":"10","author":"Oaknin","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1136\/ijgc-2022-003997_bb0055","unstructured":"Food and Drug Administration: Keytruda (pembrolizumab) . Highlights of prescribing information. n.d.Available: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/125514s110lbl.pdf"},{"key":"10.1136\/ijgc-2022-003997_bb0060","unstructured":"Euroepean Medicine Agency: Keytruda (pembrolizumab) . Summary of product characteristics. n.d.Available: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/keytruda-epar-product-information_en.pdf"},{"key":"10.1136\/ijgc-2022-003997_bb0065","unstructured":"Rucaparib vs placebo maintenance therapy in metastatic and recurrent endometrial cancer . n.d.Available: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03617679"},{"key":"10.1136\/ijgc-2022-003997_bb0070","unstructured":"UTOLA: uterin olaparib (UTOLA) . n.d.Available: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03745950"},{"key":"10.1136\/ijgc-2022-003997_bb0075","unstructured":"Study of niraparib and TSR-042 in recurrent endometrial cancer . n.d.Available: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03016338"},{"key":"10.1136\/ijgc-2022-003997_bb0080","unstructured":"Study of pembrolizumab (MK-3475) in combination with adjuvant chemotherapy with or without radiotherapy in participants with newly diagnosed endometrial cancer after surgery with curative intent (MK-3475-B21\/KEYNOTE-B21\/ENGOT-en11\/GOG-3053) . n.d.Available: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04634877"},{"key":"10.1136\/ijgc-2022-003997_bb0085","unstructured":"Study of pembrolizumab (MK-3475) versus chemotherapy in mismatch repair deficient (dmmr) advanced or recurrent endometrial carcinoma (MK-3475-C93\/KEYNOTE-C93\/GOG-3064\/ENGOT-en15) . n.d.Available: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05173987"},{"key":"10.1136\/ijgc-2022-003997_bb0090","unstructured":"Pembrolizumab (MK-3475) plus lenvatinib (E7080\/MK-7902) versus chemotherapy for endometrial carcinoma (ENGOT-en9\/MK-7902-001) (LEAP-001) . n.d.Available: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03884101"},{"key":"10.1136\/ijgc-2022-003997_bb0095","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1007\/s00038-019-01298-x","article-title":"Cost-effectiveness of precision medicine: a scoping review","volume":"64","author":"Kasztura","year":"2019","journal-title":"Int J Public Health"},{"key":"10.1136\/ijgc-2022-003997_bb0100","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1001\/jama.2014.3741","article-title":"Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs","volume":"311","author":"Kris","year":"2014","journal-title":"JAMA"},{"key":"10.1136\/ijgc-2022-003997_bb0105","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/S0140-6736(16)00004-0","article-title":"Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)","volume":"387","author":"Barlesi","year":"2016","journal-title":"Lancet"},{"key":"10.1136\/ijgc-2022-003997_bb0110","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.2217\/fon-2019-0010","article-title":"Utilization of tumor genomics in clinical practice: an international survey among ASCO members","volume":"15","author":"Barroso-Sousa","year":"2019","journal-title":"Future Oncol"},{"key":"10.1136\/ijgc-2022-003997_bb0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.18.00169","article-title":"Use of next-generation sequencing tests to guide cancer treatment: results from a nationally representative survey of oncologists in the United States","volume":"2","author":"Freedman","year":"2018","journal-title":"JCO Precis Oncol"},{"key":"10.1136\/ijgc-2022-003997_bb0120","first-page":"1","article-title":"A review of immune checkpoint blockade therapy in endometrial cancer","volume":"40","author":"Green","year":"2020","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1136\/ijgc-2022-003997_bb0125","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1009986","article-title":"Co-existing TP53 and ARID1A mutations promote aggressive endometrial tumorigenesis","volume":"17","author":"Reske","year":"2021","journal-title":"PLoS Genet"},{"key":"10.1136\/ijgc-2022-003997_bb0130","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.ygyno.2021.06.030","article-title":"Comprehensive immunomolecular profiling of endometrial carcinoma: a tertiary retrospective study","volume":"162","author":"Victoor","year":"2021","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2022-003997_bb0135","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.ygyno.2003.11.009","article-title":"BRCA germline mutations in Jewish women with uterine serous papillary carcinoma","volume":"92","author":"Lavie","year":"2004","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2022-003997_bb0140","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1200\/JCO.2014.58.3401","article-title":"Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma","volume":"33","author":"Slomovitz","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2022-003997_bb0145","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1038\/bjc.2013.183","article-title":"Everolimus as second- or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECO","volume":"108","author":"Ray-Coquard","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1136\/ijgc-2022-003997_bb0150","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/modpathol.2009.5","article-title":"Concomitant PI3K-Akt and p53 alterations in endometrial carcinomas are associated with poor prognosis","volume":"22","author":"Catasus","year":"2009","journal-title":"Mod Pathol"},{"key":"10.1136\/ijgc-2022-003997_bb0155","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-019-0835-1","article-title":"Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicine","volume":"12","author":"Tsimberidou","year":"2019","journal-title":"J Hematol Oncol"},{"key":"10.1136\/ijgc-2022-003997_bb0160","unstructured":"Refining adjuvant treatment in endometrial cancer based on molecular features (RAINBO) . n.d.Available: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05255653"},{"key":"10.1136\/ijgc-2022-003997_bb0165","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1001\/jamaoncol.2022.2181","article-title":"Evaluation of treatment with talazoparib and avelumab in patients with recurrent mismatch repair proficient endometrial cancer","volume":"8","author":"Konstantinopoulos","year":"2022","journal-title":"JAMA Oncol"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24024344?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24024344?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ijgc-2022-003997","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T00:19:18Z","timestamp":1753229958000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24024344"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S1048891X24024344"],"URL":"https:\/\/doi.org\/10.1136\/ijgc-2022-003997","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genome tumor profiling in endometrial cancer and clinical relevance in endometrial cancer management: a retrospective single-center experience","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ijgc-2022-003997","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 IGCS and ESGO 2023. No commercial re-use. See rights and permissions. Published by BMJ.","name":"copyright","label":"Copyright"}]}}